Despite therapeutic advances, including the use of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 agonists, and non‐steroidal mineralocorticoid receptor antagonists, managing DKD remains challenging. Here, ACE is linked to diabetic kidney disease.